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Crystal Structure of the Extracellular
Domain of a Human FcgRIII
to 10210 M, whereas the other receptors, such as FcgRII
and FcgRIII, are low-affinity receptors with dissociation
constants ranging from 1025 to 1027 M (Hulett and Ho-
Yihong Zhang,* Christian C. Boesen,†
Sergei Radaev,† Andrew G. Brooks,‡
Wolf-Herman Fridman,§
Catherine Sautes-Fridman,§ and Peter D. Sun†k garth, 1994; Galon et al., 1997; Powell et al., 1999).
FcgRIII, also known as CD16, is the type III Fcg recep-*Department of Human Biological Chemistry
and Genetics tor. It exists as two isoforms in humans, FcgRIIIa and
FcgRIIIb, sharing 96% sequence identity in their extra-University of Texas Medical Branch, Galveston
Galveston, Texas 77555 cellular immunoglobulin binding regions. FcgRIIIa is ex-
pressed on macrophages, mast cells, and natural killer†Structural Biology Section
National Institute of Allergy cells as a transmembrane receptor. Present exclusively
on neutrophils, FcgRIIIb is the only Fc receptor anchoredand Infectious Diseases
National Institutes of Health by a glycosyl-phosphatidylinositol (GPI) linker to the
plasma membrane. Despite the lack of a signaling com-12441 Parklawn Drive
Rockville, Maryland 20852 ponent, FcgRIIIb plays an active role in triggering Ca21
mobilization and neutrophil degranulation (Kimberly et‡Department of Microbiology and Immunology
University of Melbourne al., 1990; Unkeless et al., 1995). In addition, in conjunc-
tion with FcgRIIa, FcgRIIIb activates phagocytosis, de-Royal Parade
Parkville, Victoria 3052 granulation, and oxidative burst, which lead to the clear-
ance of opsonized pathogens by neutrophils. Recently,Australia
§INSERM Unit 255 a soluble form of FcgRIIIb was reported to activate the
complement receptor CR3-dependent inflammatory pro-Laboratory of Cellular and Clinical Immunology
Curie Institute cess (Galon et al., 1996). The immunoglobulin binding
affinities of FcgRIIIb were reported to be 1 3 1026 andParis 75005
France 2 3 1026 M for human IgG1 and IgG3, respectively (Galon
et al., 1997).
The recent crystal structures of a FceRIa, FcgRIIa,
and FcgRIIb revealed a conserved immunoglobulin-likeSummary
(Ig-like) structure, particularly the small hinge angle be-
tween the two Ig-like domains that is unique to the FcFc receptors play a major role in immune defenses
against pathogens and in inflammatory processes. receptors (Garman et al., 1998; Maxwell et al., 1999;
Sondermann et al., 1999a). Several models of receptorThe crystal structure of a human immunoglobulin re-
ceptor, FcgRIIIb, has been determined to 1.8 A˚ resolu- activation/oligomerization have been proposed, based
on the crystal lattice packings and molecular modeling.tion. The overall fold consists of two immunoglobulin-
like domains with an acute interdomain hinge angle However, discrepancies exist among these models and
none appear to form an oligomeric state. We report hereof approximately 508. Trp-113, wedged between the
N-terminal D1 and the C-terminal D2 domains, appears a 1.8 A˚ crystal structure of a human FcgRIIIb and its
implication to the receptor oligomerization, based onto further restrict the hinge angle. The putative Fc
binding region of the receptor carries a net positive our observed crystal lattice packing.
charge complementary to the negative-charged re-
ceptor binding regions on Fc. A 1:1 binding stoichiom- Results and Discussion
etry between the receptor and Fc was measured by
both the equilibrium and nonequilibrium size-exclu- Overall Structure of FcgRIII
sion chromatography. Two separate parallel dimers The sequence of human FcgRIII is 49% identical to
are observed in the crystal lattice, offering intriguing FcgRIIa and 39% identical to FceRIa (Figure 1). Two
models for receptor aggregation. forms of the FcgRIII receptor crystal were obtained. The
structure was initially determined on the lower resolution
Introduction crystal form to 2.3 A˚ resolution by multiwavelength
anomalous dispersion (MAD) method using a HgCl2
Because of their ability to bind the Fc portion of antibod- derivative (Table 1). The refined R values are 0.24 and
ies, Fc receptors provide a link between humoral and 0.29 for Rcryst and Rfree, respectively, for this crystal form.
cellular immune responses. There are Fc receptors for The two receptor molecules, A and B, in each crys-
each Ig isotype. Except for FceRII (CD23), which is tallographic asymmetric unit were refined independ-
C-type lectin–like, all other known Fc receptors are ently without noncrystallographic symmetry (NCS) con-
members of the immunoglobulin superfamily (Daeron, straints. A second form of the receptor crystal, which
1997). Among them, FcgRI and FceRI are high-affinity relates to the first crystal form by converting the non-
receptors with dissociation constants ranging from 1028 crystallographic two-fold into a crystallographic two-
fold symmetry, was obtained under slightly different
crystallization conditions. The refined receptor modelk To whom correspondence should be addressed (e-mail: psun@
nih.gov). from the first crystal form was further refined to 1.8 A˚
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Figure 1. Sequence Alignment of Human Fc Receptors
Amino acids identical to the sequence of FcgRIIa are not shown. The secondary structure elements of FcgRIII are shown above the sequence
with the D1 domain in black and the D2 domain in gray. Residues involved in the interdomain hinge packing are boxed in red. Residues in
the putative Fc binding region are shown in magenta.
resolution in the second crystal form with the final R FcgRIII can be readily superimposed to the C-terminal
D2 domain, resulting in a root-mean-square (rms) differ-values of 0.18 and 0.21 for Rcryst and Rfree, respectively.
The refined model contains amino acids 3–174 of the ence of 1.2 A˚ between 73 pair of Ca atoms.
The refined structures of the two receptor moleculesmature sequence of FcgRIII ligand binding domain. The
electron density is well defined throughout the molecule in the first crystal form are nearly identical to each other
and to that of the second crystal form, with the differ-in the refined (2Fo-Fc) map. The overall structure of
FcgRIII consists of two immunoglobulin-like domains ences among the individual domains less than 0.7 A˚ in
rms deviation.(Figure 2A), similar to those of FcgRIIa, FcgRIIb, and
FceRIa (Garman et al., 1998; Maxwell et al., 1999; Among members of known Ig superfamily receptors,
the structure of Fc receptors is most similar to that ofSondermann et al., 1999a). Different from the C2-like
hematopoietic growth factor receptor fold, the first b killer cell immunoglobulin-like (KIR) receptors, despite
the existence of only 18% sequence identity. They notstrand of both domains contains a switch from A to A9,
pairing with strand B and G, respectively. This strand only share the same fold, but the individual domains can
be readily superimposed, resulting in rms differences ofswitch is centered at Pro-14 and Pro-96 of the D1 and
D2 domains and is also observed in the structure of 1.9 and 1.5 A˚ among their individual D1 (72 superim-
posed Ca atoms) and D2 (71 superimposed Ca atoms)killer cell immunoglobulin-like receptors (KIR) (Fan et
al., 1997; Maenaka et al., 1999; Snyder et al., 1999). Pro- domains, respectively.
14 is in the cis conformation, whereas Pro-96 is in the
trans conformation and can be replaced by a Ser at this The Interdomain Hinge Angle
A feature common to all known Ig superfamily Fc recep-location, as in the structure of FceRI and in the sequence
of FcgRI. The structure of the N-terminal D1 domain of tors is their acute hinge angle between the N- and
Table 1. Data Collection and Refinement Statistics
Data Wavelength Resolution Unique Completeness Phasingc Rcullisb
Set l (A˚) (A˚) Reflections (%) I/s(I) Rsyma Power iso/ano f.o.m.d
Native 1 1.040 2.3 19133 96.7 (90.0) 31.2 (4.3) 0.043 (.25)
Native 2 1.54 1.8 36180 95.8 (80.1) 29.5 (6.9) 0.054 (.21)
HgCl-3 1.0078 2.35 34036 98.8 (97.6) 21.1 (3.4) 0.038 (.25) 1.8 0.64/0.83 0.51
HgCl-4 1.0246 2.35 34340 99.1 (98.1) 20.9 (3.7) 0.039 (.27) 1.5 0.67/0.92




(A˚) Molecules Rcryst Rfree B Factor Bond (A˚) Angle (8) Dihedral (8)
Native 1 10.0–2.3 299 0.242 0.290 53.6 0.01 2.2 26.3
Native 2 20.0–1.8 223 0.184 0.216 24.1 0.013 1.73 27.6
a Rsym 5 RjIh 2 ,Ih.j/RIh, where ,Ih. is the mean intensity for multiple measurements of symmetry-related reflection h. The values in parentheses
for the completeness, I/s, and Rsym correspond to those of the highest resolution shells, which are 2.38–2.3 A˚ for the Native 1, 1.86–1.80 for
the Native 2, and 2.43–2.35 A˚ for the Hg derivative data sets.
b Rcullis is calculated as the ratio of the lack of closure and the isomorphous or anomalous differences. HgCl-3, -4, and -5 data sets correspond
to the calculated peak, remote, and edge wavelengths of Hg LIII dispersion edge. HgCl-5 is treated as the reference data set throughout the
phase refinement.
c The overall phasing power is calculated as the average of (Fh/lack of closure) and includes both centric and acentric reflections.
d The figure of merit is calculated for all three wavelength data sets.
e Refinement is carried out against the native data set. Rfree is calculated using 5% randomly selected test reflections. The percentage residues
in the four Ramachandran Plot regions (the most favored, additional allowed, generously allowed, and disallowed) are 78.3, 16.1, 4.0, and 1.6
for Native 1; and 86.6, 12.1, 1.3, and 0.0 for Native 2.
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Figure 2. Structure of FcgRIII
(A) The N-terminal D1 and the C-terminal D2 domains are colored in blue and green, respectively. The putative ligand binding loops of FcgRIII
are colored in red. The strands for the D1 domain are A (5–12), A9 (17–20), B (22–33), C (39–45), C9 (47–52), E (55–61), F (66–73), and G (77–85)
and the strands for the D2 domain are A (91–95), A9 (98–101), B (104–113), C (120–125), C9 (130–134), E (136–143), F (149–157), and G (163–172).
Residues 146–149 form a short a helix.
(B) Orientation of the D1 and D2 domains in KIR. The D2 domain of KIR is in a similar orientation to that of FcgRIII.
(C) The interdomain hinge region. The D1–D2 domain of FcgRIII and their respective interdomain packing residues are shown in dark blue
and green. The BC loop of the D2 domain is colored in orange. The dashed line indicates the salt bridge between Asp-23 and His-111. The
superposition of the D1 domain on the D2 domain is shown in light blue and its BC loop in purple.
(D) Superposition of the molecule A and B of FcgRIII in the asymmetric unit. A bound phosphate ion is found in molecule B but not in A. All
ribbon figures are prepared using the program MOLSCRIPT and Raster3D (Kraulis, 1991; Merritt and Bacon, 1997).
C-terminal Ig domains. This angle was reported between is also opposite to other receptors (Figures 2A and 2B).
Detailed examination of the hinge region reveals the528 and 708 for FcgRIIa and FcgRIIb, respectively, a
discrepancy most likely caused by the different algo- molecular basis for the unique interdomain hinge angle
common to all Fc receptors. First, as noted in the FcgRIIarithms used in estimating the angles (Maxwell et al.,
1999; Sondermann et al., 1999a). The hinge angle of structure, the interdomain linker for all Fc receptors con-
sists of two residues; that is shorter than the five-residueFcgRIIa and FcgRIIb are calculated to be 558 and 528,
respectively, using the HINGE program (Snyder et al., linker observed in KIR and growth hormone receptor.
The KIR-like D1–D2 arrangement requires a longer inter-1999). The interdomain hinge angle is calculated to be
518, 478, and 498 for receptor A, receptor B of the first domain linker, while the linker for Fc receptors appears
too short to adopt the KIR-like interdomain arrange-crystal form, and the receptor of the second crystal
form, respectively. Compared to other Ig-like structures, ment. Second, the BC loop from the D2 domain, residues
113–118, protrudes away from the core of the D2 domainsuch as the hematopoietic receptors, KIR receptors,
and adhesion receptors, Fc receptors not only have toward the D1 domain instead of assuming a typical up-
and-down direction (Figure 2C) as in the BC loop of thesmaller hinge angles, but the position of their N-terminal
(D1) domain with respect to the C-terminal (D2) domain D1 domain. As a result, this BC loop acts as a cap
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the D1 domain as a wedge to further restrict the hingeTable 2. Interactions between D1 and D2 Domains of FcgRIII
movement (Figure 2C). Any increase in the hinge angle
Hydrogen Bonds and Salt Bridges would create steric hindrance between Trp-113 and the
D1 D2 Distancea (A˚) backbone of the AB loop in the D1 domain. A Trp-113
to Ala mutation in FceRI, which would likely result in aSer-18 O Gln-94 Ne2 3.0
conformational change, has been shown to affect theAsp-23 Od1 His-111 Ne2 2.9
IgE binding dramatically (Hulett et al., 1999). In addition,Od2 His-111 Ne2 3.1
there are also favorable interdomain interactions to sta-Hydrophobic Contactsb
bilize the tight D1–D2 packing (Table 2). One such inter-Trp-16 Gln-94, Ala-95, Pro-96, His-107, Arg-109
action is a conserved salt bridge between Asp-23 of theTyr-17 Ala-95, Trp-98
Ser-18 Leu-92 D1 domain and His-111 of the D2 domain. There is also
Val-19 Leu-92 a small core of hydrophobic residues, consisting of Trp-
Leu-20 Leu-92, His-111, Ser-112, Trp-113 16, Leu-20, Leu-92, Gln-94, and Trp-113, in the hinge
Glu-21 Trp-113
region. Hydrogen bonds and van der Waals interactionsLys-22 Trp-113, Lys-114
among hydrophilic residues are also found in the hinge
a Hydrogen bond distance cutoff is 3.5 A˚. region providing additional stability to the hinge angle.
b Carbon–carbon contacts , 4.0 A˚. The D1–D2 interface buries 1290 A˚2 solvent-exposed
area. The small hinge angle difference between mole-
cules A and B is most likely the result of a bound phos-
situated on top of the D1 domain, restricting its position. phate ion that is found in the hinge region of molecule
A similar conformation is also found in the BC loop from B but not in A (Figure 2D). The existence of a bound
the structure of FceRI. Third, a conserved tryptophan phosphate ion was also evident from mass spectrometry
residue, Trp-113, (also referred to as Trp-110 in the of FcgRIII (data not shown). Although the biological rele-
structures of FcgRIIb and FceRI) (Figure 1) from the BC vance of the phosphate-bound and phosphate-free
forms of the receptor remains unclear, the difference inloop of the D2 domain inserts itself into one end of
Figure 3. The Structure of Fc Binding Region
(A) The putative Fc binding region. The D1
and D2 domains of FcgRIII are shown in dark
blue and green, respectively. Residues in the
putative ligand binding region of FcgRIII are
shown in ball-and-stick model. The D2 do-
main of FceRI superimposed onto the D2 do-
main of FcgRIII is shown in light blue.
(B) The Grasp representation of the electro-
static potential distribution at the putative in-
terface of FcgRIII and the CH2 domain of IgG.
Positive potentials are colored in blue, and
negative potentials are in red. The putative
interface regions are highlighted. The coordi-
nates for Fc are taken from the structure of
IgG2a, Protein Data Bank entry 1IGT.
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Figure 4. Analysis of the FcgRIII and Fc Com-
plex by Size-Exclusion Chromatography un-
der Both Nonequilibrium and Equilibrium
Conditions
The apparent molecular weights of FcgRIII,
Fc, and their complex are 25, 51, and 63
kDa, respectively. The predicted molecular
masses for FcgRIII and Fc are 21.0 and 50.4
kDa, respectively.
(A) Nonequilibrium gel filtration. The injection
sample contains 10 mM FcgRIII or 10 mM Fc
for the FcgRIII and Fc-only runs. The com-
plexes were prepared with 10 mM Fc and vari-
ous amounts of the receptor to give rise to
the 1:1, 2:1, and 3:1 receptor:Fc molar ratio.
(B) Equilibrium gel filtrations were carried out
using a buffer containing 50 mM NaCl, 50 mM
Tris (pH 8.0), and 10 mM FcgRIII. Samples
contain 10 mM Fc with various amounts of
FcgRIII as indicated in each curve. The elution
volumes of FcgRIII and the FcgRIII:Fc com-
plex are marked.
hinge angle observed between the two molecules in the BC, C9E, and FG loops exist between the two receptors,
while the b strands are closely superimposed (Figureasymmetric unit suggests that the hinge angle can vary.
3A). In particular, the C9E loop differs as much as 5 A˚
between the two receptors, with the loop adopting anThe Putative Ligand Binding Region
Extensive mutational analysis on Fc receptors in recent up conformation in FcgRIII and down conformation in
FceRI. It is possible that this conformational differenceyears has identified regions of the receptors that are
important for the binding of immunoglobulins. In particu- contributes to part of the difference in ligand binding
affinity.lar, the construction of FcgRII and FceRI chimeric recep-
tors and the use of site-directed mutagenesis have iden-
tified residues on the BC, C9E, and FG loops of the
D2 domain that are important for the function of Fc Stoichiometry of Fc and FcgRIII Recognition
Recent solution binding studies suggest the binding ofreceptors (Hulett et al., 1994, 1995; Cook et al., 1997;
Henry et al., 1997). However, the details of molecular IgG be 1:1 for both FcgRIII and FcgRII (Ghirlando et
al., 1995; Kato et al., 2000), although both 1:1 and 2:1recognition between Fc and Fc receptors remain to be
elucidated. Structurally, these loops encompass a rather receptor–ligand binding modes have been proposed
(Metzger, 1992; Maxwell et al., 1999; Sondermann et al.,extensive area and together with the hinge loop (resi-
dues 88–90) and the AB loop of the D1 domain (residue 1999b). We have examined the binding of FcgRIII with
an Fc derived from a human IgG1, using both analytical21–23) they form a putative ligand binding region (Figure
3A). There are a total of 16 residues in this region. With ultracentrifugation (AUC) and size-exclusion chroma-
tography techniques. The affinity between the receptorsix potential positively charged amino acids and only
one negatively charged amino acid, the putative ligand and Fc measured by the AUC experiments is 0.4 mM. The
receptor–ligand binding stoichiometry, however, couldbinding region of FcgRIII appears overwhelmingly posi-
tively charged. Interestingly, the sequence alignment of not be confirmed from the AUC experiments. To deter-
mine the receptor–ligand binding stoichiometry, wethe immunoglobulin Fc region shows that the presumed
Fc receptor binding site, the lower hinge region, and the have used both the nonequilibrium and the equilibrium
size-exclusion chromatography techniques (Hummelloops nearby carry a net negative charge (Figure 3B)
(Kato et al., 2000). This results in an apparent charge and Dreyer, 1962; Martin and Bjorkman, 1999; Sonder-
mann et al., 1999b). Under the nonequilibrium condi-complementarity between the receptor and Fc.
Among Fc receptors, FceRI and FcgRI are high-affinity tions, a series of gel filtration experiments were carried
out using 10 mM Fc mixed with 10, 20, and 30 mM FcgRIIIreceptors, whereas FcgRII and FcgRIII are low-affinity
receptors. It has been proposed that a Trp ladder ob- to form the 1:1, 2:1, and 3:1 receptor–Fc molar ratio
of the complex (Figure 4A). The apparent molecularserved in the structure of FceRI is critical to its ligand
affinity (Garman et al., 1998). In addition, the superposi- weights of the receptor, Fc, and their complex are 25,
51, and 63 kDa, respectively. The appearance of excesstion of the receptor D2 domains between FcgRIII and
FceRI shows that significant structural differences in the receptor in the 3:1 and 2:1 but not 1:1 molar ratio is
Immunity
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Figure 5. Fc Receptor Dimerization and Aggregation Model
(A) Crystal lattice packing of molecule A (in red) and B (in green).
(B) AA, BB, and AB parallel dimers. The dimers are formed through translational symmetry. The view is 908 from that of panel (A). D1 and D2
domains are colored in light blue and green. The interface residues are shown as ball-and-sticks in dark blue and green for the D1 and D2
domains, respectively. The predicted glycosylation sites are shown in magenta. The putative Fc binding loops are colored red. AB parallel
dimer is formed between the two molecules in each asymmetric unit.
(C) A hypothetical model of receptor aggregation based on the observed parallel AB dimer (in green) in crystal lattice. The antibody coordinates,
colored in magenta and blue, are from Protein Data Bank entry 1IGT.
consistent with a 1:1 receptor–ligand binding stoichiom- contained only Fc (at 10 mM concentration), indicating
a depletion of the receptor in running buffer. The troughetry. The composition of FcgRIII and Fc in the complex
peak was also estimated by N-terminal peptide se- disappeared at the receptor–ligand ratio of 1:1 and de-
veloped into a peak at the receptor–ligand ratios of 2:1quencing. The result is also consistent with a 1:1 molar
ratio between FcgRIII and Fc. and 3:1. Similar gel filtration profiles were also observed
when the column was equilibrated with 1 mM of Fc in-The equilibrium gel filtration experiments were per-
formed with the column equilibrated using a buffer con- stead of the receptor. The results from both the non-
equilibrate and equilibrate gel filtration experiments sug-taining 10 mM FcgRIII (Figure 4B). A trough correspond-
ing to the receptor was observed when the sample gest a 1:1 receptor–ligand stoichiometry.
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cells containing the FcgRIIIb-expressing plasmid were grown in aReceptor Dimerization and Aggregation in Crystal
10 liter Newbrunswick Bioflo 3000 bioreactor vessel and inducedLigand-induced receptor aggregation is presumed to be
with 0.5 mM IPTG at an approximate OD595 of 10.0 for 5 hr. Oncea common mechanism for initiating receptor-mediated
harvested, the inclusion bodies were isolated by repeated washing
signaling. Structurally, one of the best known examples with 2 M urea solution and then redissolved in 8 M urea prior to
is the human growth hormone–induced receptor dimer- refolding. The refolding reaction was initiated by a quick dilution of
the urea-dissolved inclusion bodies of FcgRIIIb into a refoldingization, in which one molecule of growth hormone or
buffer consisting of 0.5 M arginine, 5 mM CaCl2, 5 mM cysteamine,erythropoietin binds to two molecules of their receptors
5 mM cystamine, 10 ug/ml AEBSF, and 50 mM Tris (pH 8.0) and(de Vos et al., 1992; Livnah et al., 1999). The situation
then dialyzed thoroughly against water. The renatured FcgRIIIb wasbetween Fc and Fc receptors is less clear due to the 1:1
concentrated on a Ni-NTA affinity column and further purified on a
receptor–ligand complex. In these crystals of FcgRIII, we Superdex 200 size-exclusion column. The integrity of the refolded
observed two forms of receptor dimers among symme- receptor was analyzed both by N-terminal amino acid sequencing
and by electrospray ionization mass spectrometry (ESI-MS).try molecules (Figures 5A and 5B). The first dimer is
formed between molecule A or B and their equivalent
molecules in adjacent unit cells, the AA or BB dimer Analytical Ultracentrifugation Experiments
(Figures 5A and 5B). They are parallel dimers in which Sedimentation equilibrium profiles were obtained in a Beckman
XL-A, using absorbance optics at wavelengths of 230, 250, and 280monomers of the same orientation associate through a
nm. One hundred and fifty microliters of samples in 5 mM phosphateD1–D2 interaction. The interface of this AA dimer, bury-
buffer, at different concentrations of Fc and CD16, was used at rotoring 860 A˚2 solvent-exposed surface, consists of portions
speeds of 14,000 and 18,000 rpm. Sedimentation equilibrium profiles
of the B and E b strands from the D1 domain of one of both CD16 and the Fc dimer were well described by that of
molecule and portions of the F and G b strands from thermodynamically ideal monomeric species, with buoyant molar
the D2 domain of another molecule. The putative ligand masses consistent with those calculated from the amino acid se-
quence. Analysis of the mixtures was performed by a global fit ofbinding region is in identical orientation in the dimer,
several equilibrium distributions at multiple rotor speeds, proteinand the predicted glycosylation sites are located outside
concentrations, and molar ratios.the dimer interface. An ordered oligomeric aggregate is
formed based on the AA dimer throughout the crystal,
Nonequilibrium and Equilibrium Gel Filtration Experimentsin which each receptor interacts with a proceeding re-
For nonequilibrium gel filtration experiments, FcgRIII was incubatedceptor via its D1 domain and a successive receptor via
with Fc (Fc concentration was kept at 10 mM) at 1:1, 2:1, and 3:1its D2 domain, using the same D1–D2 interface (Figure
molar ratios in a running buffer of 50 mM Tris (pH 8.0) and 50 mM
5A). The second dimer, the AB dimer, observed in the NaCl for at least 30 min. A sample of 25 ml was injected onto a
crystal of FcgRIII is formed between receptors A and B Superdex 200 PC 3.2/30 gel filtration column (Amersham Pharmacia
of each asymmetric unit. It is also a parallel dimer but Biotech) equilibrated with the same buffer at a flow rate of 0.1 ml/
min. The absorbance of the eluent was monitored at 280 nm, andwith a different interface than in the AA and BB dimers
fractions in 0.1 ml volume were analyzed by SDS-PAGE. N-terminal(Figures 5A and 5B). The interface of AB dimer, burying
peptide sequencing by Edman degradation method was used to500 A˚2 solvent-exposed surface, is formed between the
quantify the amount of FcgRIII and Fc in the isolated receptor–Fc
C9 strand of the receptor A D2 domain and the C, C9 complex.
strands of the receptor B D1 domain. The predicted For equilibrium gel filtration experiments, the Superdex 200 PC
glycosylation sites are located outside the interface 3.2/30 gel filtration column (Amersham Pharmacia Biotech) was first
equilibrated with a buffer containing 50 mM Tris (pH 8.0), 50 mMarea. Since the parallel orientations relating AA, BB, and
NaCl, and 10 mM FcgRIII. Samples (25 ml) with molar compositions ofAB dimers are incompatible with the two-fold symmetry
10 mM FcgRIII:10 mM Fc, 15 mM FcgRIII:10 mM Fc, 20 mM FcgRIII:10possessed within the immunoglobulin Fc region, it pre-
mM Fc, and 30 mM FcgRIII:10 mM Fc were incubated at room temper-
dicts that the parallel dimers are consistent only with a ature in the same buffer for at least 30 min before injection onto the
1:1 receptor–ligand stoichiometry. The existence of column at a flow rate of 0.1 ml/min.
FcgR oligomers on the cell surface remains to be proven.
However, since FcgRII and FcgRIII are low-affinity IgG
Crystallization, Data Collection, and Structure Determination
receptors whose activation requires antigen-bound im- Two forms of FcgRIII crystals were obtained by hanging-drop meth-
mune complexes, it is tempting to speculate that these ods. The first form was grown from a buffer of 10% PEG 4000, 50
mM Sodium HEPES (pH 7.0), and a protein concentration of z7 mg/parallel receptor dimers may resemble the oligomers
ml. Crystals grew to a size of 0.1 3 0.2 3 0.5 mm3 in about 1 monthformed upon binding to immune complexes. This would
and diffracted to 2.3 A˚ resolution. A HgCl2 derivative was identifiedincrease the avidity of IgG–FcR interaction and facilitate
using a mass spectrometry–assisted heavy atom screening methodthe triggering of cellular responses. Figure 5C depicts
(Sun and Hammer, 2000). The mercury-derivative crystal was pre-
a hypothetical receptor aggregation model with a 1:1 pared by soaking crystals in a well solution containing 0.5% satu-
stoichiometry based on the parallel dimer observed in rated HgCl2 for 12 hr. Both the native (Native 1) and the mercury
derivative data were collected at the Brookhaven NSLS X9B beam-our current crystal.
line under cryofreezing temperature (21808C) and processed using
HKL2000 (Table 1) (Otwinowski and Minor, 1997). The crystals be-
long to a space group P21212 with the unit cell dimensions of a 5Experimental Procedures
78.9, b 5 147.8, and c 5 36.4 A˚ and two molecules in each asymmet-
ric unit. Multiwavelength anomalous dispersion (MAD) data wereProtein Expression and Purification
The extracellular ligand binding domain of a human FcgRIIIb, resi- collected at the LIII edge of Hg (Table 1). The heavy atom binding
sites were determined by both inspection of the difference Pattersondues 1–174 of the mature sequence, was subcloned into a Novagen
pET-28b vector using the NcoI and NotI restriction sites and an E. maps and by using the SHELX program and were refined by using
the program MLPHARE (Sheldrick, 1990; Otwinowski, 1994). Thecoli BL21(DE3) strain. Two additional amino acids (Met–Ala) were
added to the 59 end of the gene, and a histidine tag (Ala-Ala-Ala- initial chain tracing and all subsequent model building were done
using the program O, version 6.2.1 (Kleywegt and Jones, 1996).Leu-Glu-His6) was added to the 39 end to facilitate the expression
and purification (Snyder et al., 1999). The protein was first expressed The structure was refined with CNS, version 0.9, using a maximum
likelihood target function (Brunger et al., 1998) and without NCSin an inclusion body form and then reconstituted in vitro. In brief,
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constraints. The refinement started with rigid body refinement for region of C epsilon 3 in the binding of human IgE to its high-affinity
receptor Fc epsilon RI. Biochemistry 36, 15568–15578.each domain and was followed by alternating positional and
grouped B factor refinement. Maps were calculated and the model Hulett, M.D., and Hogarth, P.M. (1994). Molecular basis of Fc recep-
was revised using the program O at the end of each round of posi- tor function. Adv. Immunol. 57, 1–127.
tional and B factor refinement. After all protein residues were built
Hulett, M.D., Witort, E., Brinkworth, R.I., McKenzie, I.F., and Hogarth,and refined, water molecules were added to peaks higher than 2–3
P.M. (1994). Identification of the IgG binding site of the human low-s in the residual difference map and with likely hydrogen bonding
affinity receptor for IgG Fc gamma RII. Enhancement and ablationpartners. The second form of FcgRIII crystals was obtained under
of binding by site-directed mutagenesis. J. Biol. Chem. 269, 15287–slightly different condition with 10% PEG 8000 and 50 mM sodium
15293.HEPES (pH 6.5) as the precipitation reagent. The crystals belong to
the same space group, P21212, as the first form but with different Hulett, M.D., Witort, E., Brinkworth, R.I., McKenzie, I.F., and Hogarth,
cell dimensions of a 5 67.4, b 5 85.7, and c 5 36.3 A˚ and only one P.M. (1995). Multiple regions of human Fc gamma RII (CD32) contrib-
receptor molecule in the crystallographic asymmetric unit. A native ute to the binding of IgG. J. Biol. Chem. 270, 21188–21194.
data (Native 2, Table 1) was collected on an in-house Raxis IV im- Hulett, M.D., Brinkworth, R.I., McKenzie, I.F., and Hogarth, P.M.
aging plate detector to 1.8 A˚ resolution. The interdomain hinge angle (1999). Fine structure analysis of interaction of Fc epsilon RI with
is defined as the angle between the principal ellipsoid axes of the IgE. J. Biol. Chem. 274, 13345–13352.
D1 and D2 domains of the receptor and is calculated using the
Hummel, J.P., and Dreyer, W.J. (1962). Measurement of protein-program HINGE (Snyder et al., 1999).
binding phenomena by gel filtration. Biochim. Biophys. Acta 63,
530–532.
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